Aflibercept has minor added benefit in colorectal cancer patientse ...

A recent study has showed that aflibercept does not improve the prognosis of patients with metastatic colorectal cancer. Instead, the new treatment regimen led to more side effects and discontinuations of treatment compared to standard chemotherapy.?

Aflibercept was approved in 2013 as treatment for advanced colorectal cancer in combination with standard chemotherapy. To see if indeed the new VEGF (vascular endothelial growth factor) inhibitor benefit patients, researchers conducted a study that compared the combined treatment -chemotherapy plus aflibercept- with FOLFIRI (irinotecan/5-fluorouracil/folinic acid) alone. The study design was randomized double-blind and conducted in multiple centers in America, Europe, Africa, Australia, New Zealand, and Korea. The study included 1226 patients with advanced adenocarcinoma of the colon or rectum.

It was found that half of patients receiving FOLFIRI alone died after 12 months of treatment, while those who received aflibercept plus chemotherapy lived a month or two more than the first. In addition, it was observed that in aflibercept plus chemotherapy group there were more adverse events or treatment discontinuations due to side effects. Extending the overall survival duration with two months and the risk of ( severe) adverse effects of treatment led researchers to believe that aflibercept has a minor added benefit in patients with advanced colorectal cancer.

Share and Enjoy

Source: http://www.e-medblog.com/aflibercept-has-minor-added-benefit-in-colorectal-cancer-patients/

Kerri Strug Ledecky Nadia Comaneci Rebecca Soni Snoop Lion London 2012 Table Tennis badminton